Abiopharma

🔍 RIEFLIN WILLIAM JL (Executive)

Company: Lyell Immunopharma, Inc. (LYEL)

Report Date: 2026-06-10

Detailed Transactions and Holdings:

• Acquired 9,250 shares of Option (right to buy) at $13.22 per share (Derivative)
  Date: 2026-06-10 | Code: A | Expires: 2036-06-09 | equity_swap_involved: 0 | shares_owned_after: 9,250.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.